Statins have been proposed to reduce the risk of Alzheimer’s disease (AD).
Objective:
Assess whether long-term statin use was associated with neuroimaging biomarkers of aging and dementia.
Methods:
Methods: We analyzed neuroimaging biomarkers in 1,160 individuals aged 65+ from the Mayo Clinic Study of Aging, a population-based prospective longitudinal study of cognitive aging.
Results:
Statin-treated (5+ years of therapy) individuals had greater burden of mid-and late-life cardiovascular disease (p < 0.001) than statin-untreated (≤3 months) individuals. Lower fractional anisotropy in the genu of the corpus callosum, an early marker of cerebrovascular disease, was associated with long-term statin exposure (p < 0.035). No significant associations were identified between long-term statin exposure and cerebral amyloid or tau burden, AD pattern neurodegeneration, or white matter hyperintensity burden.
Conclusions:
Long-term statin therapy was not associated with differences in AD biomarkers. Individuals with long-term statin exposure had worse white matter integrity in the genu of the corpus callosum, consistent with the coexistence of higher cerebrovascular risk factor burden in this group.
KarranE, MerckenM, De StrooperB (2011) The amyloid cascade hypothesis for Alzheimer’s disease: An appraisal for the development of therapeutics. Nat Rev Drug Discov10, 698–712.
2.
RamananVK, SaykinAJ (2013) Pathways to neurodegeneration: Mechanistic insights from GWAS in Alzheimer’s disease, Parkinson’s disease, and related disorders. Am J Neurodegener Dis2, 145–175.
3.
RosenthalSL, KambohMI (2014) Late-onset Alzheimer’s disease genes and the potentially implicated pathways. Curr Genet Med Rep2, 85–101.
4.
NajAC, SchellenbergGD, Alzheimer’s Disease Genetics Consortium (2017) Genomic variants, genes, and pathways of Alzheimer’s disease: An overview. Am J Med Genet B Neuropsychiatr Genet174, 5–26.
5.
ShinoharaM, SatoN, ShimamuraM, KurinamiH, HamasakiT, ChatterjeeA, RakugiH, MorishitaR (2014) Possible modification of Alzheimer’s disease by statins in midlife: Interactions with genetic and non-genetic risk factors. Front Aging Neurosci6, 71.
6.
PowerMC, WeuveJ, SharrettAR, BlackerD, GottesmanRF (2015) Statins, cognition, and dementia-systematic review and methodological commentary. Nat Rev Neurol11, 220–229.
7.
McGuinnessB, CraigD, BullockR, PassmoreP (2016) Statins for the prevention of dementia. Cochrane Database Syst Rev, CD003160.
8.
LiG, LarsonEB, SonnenJA, ShoferJB, PetrieEC, SchantzA, PeskindER, RaskindMA, BreitnerJC, MontineTJ (2007) Statin therapy is associated with reduced neu-ropathologic changes of Alzheimer disease. Neurology69, 878–885.
9.
ArvanitakisZ, SchneiderJA, WilsonRS, BieniasJL, KellyJF, EvansDA, BennettDA (2008) Statins, incident Alzheimer disease, change in cognitive function, and neu-ropathology. Neurology70, 1795–1802.
10.
NadkarniNK, PereraS, HanlonJT, LopezO, NewmanAB, AizensteinH, ElamM, HarrisTB, KritchevskyS, YaffeK, RosanoC (2015) Statins and brain integrity in older adults: Secondary analysis of the Health ABC study. Alzheimers Dement11, 1202–1211.
11.
GlodzikL, RusinekH, KamerA, PirragliaE, TsuiW, MosconiL, LiY, McHughP, MurrayJ, WilliamsS, Oso-rioRS, RandallC, ButlerT, DeshpandeA, VallabhajolusaS, de LeonM (2016) Effects of vascular risk factors, statins, and antihypertensive drugs on PiB deposition in cognitively normal subjects. Alzheimers Dement (Amst)2, 95–104.
BernickC, KatzR, SmithNL, RappS, BhadeliaR, CarlsonM, KullerL (2005) Statins and cognitive function in the elderly: The Cardiovascular Health Study. Neurology65, 1388–1394.
14.
RichardsonK, SchoenM, FrenchB, UmscheidCA, MitchellMD, ArnoldSE, HeidenreichPA, RaderDJ, deGomaEM (2013) Statins and cognitive function: A systematic review. Ann Intern Med159, 688–697.
15.
SwigerKJ, ManalacRJ, BlumenthalRS, BlahaMJ, MartinSS (2013) Statins and cognition: A systematic review and meta-analysis of short-and long-term cognitive effects. Mayo Clin Proc88, 1213–1221.
16.
StromBL, SchinnarR, KarlawishJ, HennessyS, TealV, BilkerWB (2015) Statin therapy and risk of acute memory impairment. JAMA InternMed175, 1399–1405.
17.
JackCRJr.,, KnopmanDS, JagustWJ, PetersenRC, WeinerMW, AisenPS, ShawLM, VemuriP, WisteHJ, WeigandSD, LesnickTG, PankratzVS, DonohueMC, Tro-janowskiJQ (2013) Tracking pathophysiological processes in Alzheimer’s disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol12, 207–216.
JackCR, WisteHJ, WeigandSD, TherneauTM, KnopmanDS, LoweV, VemuriP, MielkeMM, RobertsRO, MachuldaMM, SenjemML, GunterJL, RoccaWA, PetersenRC (2017) Age-specific and sex-specific prevalence of cerebral ß-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: A cross-sectional study. Lancet Neurol16, 435–444.
20.
VemuriP, LesnickTG, PrzybelskiSA, KnopmanDS, LoweVJ, Graff-RadfordJ, RobertsRO, MielkeMM, MachuldaMM, PetersenRC, JackCRJr (2017) Age, vascular health, and Alzheimer disease biomarkers in an elderly sample. Ann Neurol82, 706–718.
21.
VemuriP, LesnickTG, PrzybelskiSA, KnopmanDS, Pre-boskeGM, KantarciK, RamanMR, MachuldaMM, MielkeMM, LoweVJ, SenjemML, GunterJL, RoccaWA, RobertsRO, PetersenRC, JackCRJr (2015) Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain138, 761–771.
22.
VilleneuveS, ReedBR, MadisonCM, WirthM, MarchantNL, KrigerS, MackWJ, SanossianN, DeCarliC, ChuiHC, WeinerMW, JagustWJ (2014) Vascular risk and Abeta interact to reduce cortical thickness in AD vulnerable brain regions. Neurology83, 40–47.
23.
KantarciK, SchwarzCG, ReidRI, PrzybelskiSA, LesnickTG, ZukSM, SenjemML, GunterJL, LoweV, MachuldaMM, KnopmanDS, PetersenRC, JackCRJr (2014) White matter integrity determined with diffusion tensor imaging in older adults without dementia: Influence of amyloid load and neurodegeneration. JAMA Neurol71, 1547–1554.
24.
HaightTJ, LandauSM, CarmichaelO, SchwarzC, DeCarli JagustWJ, Alzheimer’s Disease Neuroimaging Initiative (2013) Dissociable effects of Alzheimer disease and white matter hyperintensities on brain metabolism. JAMA Neurol70, 1039–1045.
25.
PelletierA, PeriotO, DilharreguyB, HibaB, BordessoulesM, ChanraudS, PeresK, AmievaH, DartiguesJF, AllardM, CathelineG (2015) Age-related modifications of diffusion tensor imaging parameters and white matter hyperintensities as inter-dependent processes. Front Aging Neurosci7, 255.
26.
RobertsRO, GedaYE, KnopmanDS, ChaRH, PankratzVS, BoeveBF, IvnikRJ, TangalosEG, PetersenRC, RoccaWA (2008) The Mayo Clinic Study of Aging: Design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology30, 58–69.
27.
PetersenRC, RobertsRO, KnopmanDS, GedaYE, ChaRH, PankratzVS, BoeveBF, TangalosEG, IvnikRJ, RoccaWA (2010) Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic Study of Aging. Neurology75, 889–897.
28.
RoccaWA, YawnBP, St. SauverJL, GrossardtBR, MeltonLJ (2012) History of the Rochester Epidemiology Project: Half a century of medical records linkage in a US population. Mayo Clinic Proc87, 1202–1213.
29.
St SauverJL, GrossardtBR, YawnBP, MeltonLJ, 3rd, PankratzJJ, BrueSM, RoccaWA (2012) Data resource profile: The Rochester Epidemiology Project (REP) medical records-linkage system. Int J Epidemiol41, 1614–1624.
30.
SinyavskayaL, GauthierS, RenouxC, Dell’AmelioS, SuissaS, BrassardP (2018) Comparative effect of statins on the risk of incident Alzheimer disease. Neurology90, e179–e187.
31.
HixsonJE, VernierDT (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hhal. J Lipid Res31, 545–548.
32.
RobertsRO, KnopmanDS, PrzybelskiSA, MielkeMM, KantarciK, PreboskeGM, SenjemML, PankratzVS, GedaYE, BoeveBF, IvnikRJ, RoccaWA, PetersenRC, JackCRJr (2014) Association of type 2 diabetes with brain atrophy and cognitive impairment. Neurology82, 1132–1141.
CroallID, LohnerV, MoynihanB, KhanU, HassanA, O’BrienJT, MorrisRG, TozerDJ, CambridgeVC, HarknessK, WerringDJ, BlamireAM, FordGA, BarrickTR, MarkusHS (2017) Using DTI to assess white matter microstructure in cerebral small vessel disease (SVD) in multicentre studies. Clin Sci (Lond)131, 1361–1373.
38.
WilliamsOA, ZeestratenEA, BenjaminP, LambertC, LawrenceAJ, MackinnonAD, MorrisRG, MarkusHS, CharltonRA, BarrickTR (2017) Diffusion tensor image segmentation of the cerebrum provides a single measure of cerebral small vessel disease severity related to cognitive change. Neuroimage Clin16, 330–342.
39.
Di PaoloG, KimTW (2011) Linking lipids to Alzheimer’s disease: Cholesterol and beyond. Nat Rev Neurosci12, 284–296.
40.
RefoloLM, PappollaMA, LaFrancoisJ, MalesterB, SchmidtSD, Thomas-BryantT, TintGS, WangR, MerckenM, PetanceskaSS, DuffKE (2001) A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer’s disease. Neurobiol Dis8, 890–899.
41.
KojroE, GimplG, LammichS, MarzW, FahrenholzF (2001) Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10. Proc Natl Acad Sci USA98, 5815–5820.
42.
Hirsch-ReinshagenV, BurgessBL, WellingtonCL (2009) Why lipids are important for Alzheimer disease?Mol Cell Biochem326, 121–129.
43.
LiuCC, LiuCC, KanekiyoT, XuH, BuG (2013) Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat Rev Neurol9, 106–118.
44.
CorderEH, SaundersAM, StrittmatterWJ, SchmechelDE, GaskellPC, SmallGW, RosesAD, HainesJL, Pericak-VanceMA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science261, 921–923.
45.
DietschyJM (2009) Central nervous system: Cholesterol turnover, brain development and neurodegeneration. Biol Chem390, 287–293.
46.
ReedB, VilleneuveS, MackW, DeCarliC, ChuiHC, JagustW (2014) Associations between serum cholesterol levels and cerebral amyloidosis. JAMA Neurol71, 195–200.
HaagMD, HofmanA, KoudstaalPJ, StrickerBH, BretelerMM (2009) Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry80, 13–17.
49.
OttBR, DaielloLA, DahabrehIJ, SpringateBA, BixbyK, MuraliM, TrikalinosTA (2015) Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. J Gen Intern Med30, 348–358.
50.
WanamakerBL, SwigerKJ, BlumenthalRS, MartinSS (2015) Cholesterol, statins, and dementia: What the cardiologist should know. Clin Cardiol38, 243–250.
51.
GeifmanN, BrintonRD, KennedyRE, SchneiderLS, ButteAJ (2017) Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer’s disease. Alzheimers Res Ther9, 10.
52.
ZissimopoulosJM, BartholdD, BrintonRD, JoyceG (2017) Sex and race differences in the association between statin use and the incidence of Alzheimer disease. JAMA Neurol74, 225–232.
53.
JickH, ZornbergGL, JickSS, SeshadriS, DrachmanDA (2000) Statins and the risk of dementia. Lancet356, 1627–1631.
54.
SierraS, RamosMC, MolinaP, EsteoC, VazquezJA, BurgosJS (2011) Statins as neuroprotectants: A comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. J Alzheimers Dis23, 307–318.
55.
RabinoviciGD, CarrilloMC, FormanM, DeSantiS, MillerDS, KozauerN, PetersenRC, RandolphC, KnopmanDS, SmithEE, IsaacM, MattssonN, BainLJ, HendrixJA, SimsJR (2017) Multiple comorbid neuropathologies in the setting of Alzheimer’s disease neuropathology and implications for drug development. Alzheimers Dement (N Y)3, 83–91.
56.
ReitzC (2016) Toward precision medicine in Alzheimer’s disease. Ann Transl Med4, 107.
57.
PriceJL, MorrisJC (1999) Tangles and plaques in nonde-mented aging and “preclinical” Alzheimer’s disease. Ann Neurol45, 358–368.
58.
MusiekES, HoltzmanDM (2012) Origins of Alzheimer’s disease: Reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement. Curr Opin Neurol25, 715–720.
